Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, ...

The World Health Organization is now recommending GLP-1 drugs as a tool to manage obesity in adults. The guidance, which says ...

(HealthDay News) — The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an adjunct to lifestyle modification versus placebo for ...

Amid soaring global demand for glucagon-like peptide-1 (GLP-1) medications and widespread concerns about affordability and access, the World Health Organization (WHO) released its global comprehensive ...

Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma Inc. announced positive results from its 13-week Phase II study ...

The World Health Organization conditionally recommended GLP-1 drugs for obesity. A physician breaks down what you need to ...

The recommended use of GLP-1 therapies, including tirzepatide (Zepbound), semaglutide (Wegovy), and liraglutide (Saxenda), for adults with obesity is "grounded in the recognition of obesity as a ...

This week, the World Health Organization entered a new arena with its first global guideline on GLP-1 therapies for obesity ...

Obesity is one of the most common and complex chronic diseases clinicians encounter in practice. Yet it is still often ...

THE WORLD HEALTH ORGANISATION, or WHO, has issued global guidelines on the usage of GLP-1 medicines, also known as “skinny ...

The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health ...